HIGHLIGHTS
- who: Yi Zhang from the We retrospectively enrolled , patients diagnosed with advanced NSCLC who regularly received DP (docetaxel plus cisplatin), GP (gemcitabine plus cisplatin), NP (vinorelbine plus cisplatin), PC (pemetrexed plus cisplatin) and TP (paclitaxel plus cisplatin) chemotherapy regimens at the Affiliated Hospital of Xu Zhou Medical University from January May , and July The inclusion criteria were as follows: (1) NSCLC was pathologically diagnosed have published the article: Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy, in the Journal: (JOURNAL)
- what: The aim of this . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.